
[Federal Register: September 17, 2010 (Volume 75, Number 180)]
[Rules and Regulations]               
[Page 56858]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr17se10-3]                         

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 2

[Docket No. FDA-2006-N-0304] (formerly Docket No. 2006N-0262)
RIN 0910-AF93

 
Use of Ozone-Depleting Substances; Removal of Essential-Use 
Designation (Flunisolide, etc.); Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a final 
rule that appeared in the Federal Register of April 14, 2010 (75 FR 
19213). The document amended FDA's regulation on the use of ozone-
depleting substances (ODSs) in self-pressurized containers to remove 
the essential-use designations for flunisolide, triamcinolone, 
metaproterenol, pirbuterol, albuterol and ipratropium in combination, 
cromolyn, and nedocromil used in oral pressurized metered-dose inhalers 
(MDIs). The document was published with an inadvertent error. This 
document corrects that error.

FOR FURTHER INFORMATION CONTACT:  Diane Sullivan, Office of Policy, 
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 
3210, Silver Spring, MD 20993, 301-796-9171.

SUPPLEMENTARY INFORMATION: In FR Doc. 2010-8467, appearing on page 
19213, in the Federal Register of Wednesday, April 14, 2010, the 
following correction is made:
    1. On page 19213, in the third column, the heading ``RIN 0910-
AF92'' is corrected to read ``RIN 0910-AF93''.

    Dated: September 13, 2010.
David Dorsey,
Acting Deputy Commissioner for Policy, Planning and Budget.
[FR Doc. 2010-23195 Filed 9-16-10; 8:45 am]
BILLING CODE 4160-01-S

